Euroopan unioni - suomi - EMA (European Medicines Agency)

swedish orphan biovitrum ab - kollagenaasi clostridium histolyticum - dupuytren contracture - muut lääkkeet liikuntaelinten sairauksien häiriöihin - , the treatment of dupuytren’s contracture in adult patients with a palpable cord. hoito aikuisten miesten kanssa peyronien tauti, jossa on käsin kosketeltava plakkia ja kaarevuus epämuodostuma vähintään 30 astetta hoidon alussa.

Euroopan unioni - suomi - EMA (European Medicines Agency)

diurnal europe b.v. - hydrokortisoni - adrenal hyperplasia, congenital - kortikosteroidit systeemiseen käyttöön - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - carbimazole - tabletti - 5 mg - karbimatsoli

Euroopan unioni - suomi - EMA (European Medicines Agency)

lupin europe gmbh - mexiletine hydrochloride - myotonic disorders - sydämen hoito - namuscla on tarkoitettu oireenmukaiseen hoitoon myotonia aikuispotilailla, joilla on ei-humuspitoiset myotonic disorders.

Euroopan unioni - suomi - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - hemostaatit - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gedeon richter plc. - follitropiini alfa - anovulation - sukupuolihormonit ja genitaalijärjestelmään vaikuttavat aineet, - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. kliinisissä tutkimuksissa näiden potilaiden käytettiin endogeenista seerumin lh-tasoa < 1. 2 iu / l. in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.